Company Profiles

driven by the PitchBook Platform

Angion Biomedica

Angion Biomedica
1998 FOUNDED
PRIVATE STATUS
11-50 EMPLOYEES
Series A LATEST DEAL TYPE
$4.36M LATEST DEAL AMOUNT
$4.36M TOTAL AMOUNT RAISED
Description

Owner and operator of a bio-pharmaceutical company. The company offers clinical-stage organ restoration focused on renal disease including acute kidney injury and chronic renal disease.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
51 Charles Lindbergh Boulevard
Uniondale, NY 11553
United States

+1 (516) 326-1200
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Angion Biomedica’s full profile, request a free trial.

Angion Biomedica Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 20-Feb-2015 $4.36M $4.36M 000.00 Completed Clinical Trials - Phase 3
1. IPO 24-Oct-2014 Cancelled Clinical Trials - Phase 3
To view this company’s complete deal history including valuation and funding request access »

Angion Biomedica Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000 00.000000 00 0000.00 0000.00 00 0000.00 0.000
To view this company’s complete Cap Table request access »

Angion Biomedica Executive Team (3)

Name Title Board
Seat
Contact
Info
Itzhak Goldberg MD Chief Executive Officer, Chairman, President, Board Memeber and Scientific Director
Andrew Savadelis Chief Financial Officer
Micheal Yamin Ph.D Vice President, Corporate Affairs & Director

You’re viewing 3 of 3 executives.

Angion Biomedica Board Members (1)

Name Representing Role Since Contact
Info
Itzhak Goldberg MD Angion Biomedica Chief Executive Officer, Chairman, President, Board Memeber and Scientific Director 000 0000

You’re viewing 1 of 1 board members.